CJC1295 + IPAMORELIN (NO DAC) BLEND - 10MG (5mg/5mg)
‘The Synergistic Secretagogue Duo’: A research peptide blend combining two synthetic peptides studied in cellular biology and biochemical research literature:
Kare Tides CJC1295/IPAMORELIN (No Dac) is a sophisticated combination of two potent growth hormone secretagogues. This dual-peptide formulation is engineered to leverage the synergistic relationship between a Growth Hormone-Releasing Hormone (GHRH) analogue and a Growth Hormone Secretagogue (GHS), specifically designed for researchers investigating enhanced endogenous hormone signaling.
Mechanism of Action: Dual-Pathway Stimulation
In research protocols, this blend is studied for its ability to maximize the amplitude of growth hormone (GH) pulses. The two compounds work via distinct but complementary pathways:
CJC-1295 (No DAC): Functions as a GHRH mimetic. It binds to GHRH receptors in the anterior pituitary to initiate the production and release of growth hormone. The “No DAC” (Drug Affinity Complex) version is specifically chosen for its shorter half-life, more closely mimicking the natural physiological spikes of human GH.
Ipamorelin: Acts as a selective Ghrelin receptor agonist. It reinforces the GH pulse by inhibiting somatostatin (the hormone that suppresses GH) and directly stimulating the pituitary to release stored GH.
Key Research Focus Areas
Hypertrophic Signaling: Investigation into the upregulation of IGF-1 and its role in cellular repair, muscle protein synthesis, and bone density.
Metabolic Efficiency: Researching the blend’s impact on basal metabolic rate, adipose tissue oxidation, and nitrogen retention.
Selective Potency: Unlike older secretagogues, Ipamorelin is highly selective; studies suggest it does not significantly impact prolactin, cortisol, or ACTH levels, making it a preferred subject for clean signaling research.
Recovery and Sleep Architecture: Evaluation of how pulsatile GH release influences circadian rhythm and deep-wave sleep recovery cycles.
INTENDED USE:
This compound is intended for in vitro research only by qualified professionals. It is not for human or veterinary use, and must not be used in food, drugs, diagnostics, or cosmetics.
DISCLAIMER:
This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must follow institutional and regulatory guidelines.
TERMS OF SALE:
By purchasing, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance.
‘The Synergistic Secretagogue Duo’: A research peptide blend combining two synthetic peptides studied in cellular biology and biochemical research literature:
Kare Tides CJC1295/IPAMORELIN (No Dac) is a sophisticated combination of two potent growth hormone secretagogues. This dual-peptide formulation is engineered to leverage the synergistic relationship between a Growth Hormone-Releasing Hormone (GHRH) analogue and a Growth Hormone Secretagogue (GHS), specifically designed for researchers investigating enhanced endogenous hormone signaling.
Mechanism of Action: Dual-Pathway Stimulation
In research protocols, this blend is studied for its ability to maximize the amplitude of growth hormone (GH) pulses. The two compounds work via distinct but complementary pathways:
CJC-1295 (No DAC): Functions as a GHRH mimetic. It binds to GHRH receptors in the anterior pituitary to initiate the production and release of growth hormone. The “No DAC” (Drug Affinity Complex) version is specifically chosen for its shorter half-life, more closely mimicking the natural physiological spikes of human GH.
Ipamorelin: Acts as a selective Ghrelin receptor agonist. It reinforces the GH pulse by inhibiting somatostatin (the hormone that suppresses GH) and directly stimulating the pituitary to release stored GH.
Key Research Focus Areas
Hypertrophic Signaling: Investigation into the upregulation of IGF-1 and its role in cellular repair, muscle protein synthesis, and bone density.
Metabolic Efficiency: Researching the blend’s impact on basal metabolic rate, adipose tissue oxidation, and nitrogen retention.
Selective Potency: Unlike older secretagogues, Ipamorelin is highly selective; studies suggest it does not significantly impact prolactin, cortisol, or ACTH levels, making it a preferred subject for clean signaling research.
Recovery and Sleep Architecture: Evaluation of how pulsatile GH release influences circadian rhythm and deep-wave sleep recovery cycles.
INTENDED USE:
This compound is intended for in vitro research only by qualified professionals. It is not for human or veterinary use, and must not be used in food, drugs, diagnostics, or cosmetics.
DISCLAIMER:
This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must follow institutional and regulatory guidelines.
TERMS OF SALE:
By purchasing, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance.